How does topotecan actually stop cancer cells from growing?
Topotecan blocks an enzyme called topoisomerase I that normally fixes broken DNA strands in cancer cells. When topotecan traps this enzyme on DNA, the cell cannot repair the damage, leading to double-strand breaks and cell death during DNA replication [8][9].
Topoisomerase I normally relieves tension in DNA by cutting one strand, then resealing it. Topotecan binds tightly to the topoisomerase I–DNA complex and prevents the enzyme from resealing the break. When cancer cells try to copy their DNA during replication, the replication machinery crashes into these trapped breaks, creating permanent double-strand damage that mammalian cells cannot repair efficiently [9].
Cancer cells divide much faster than normal cells, so they need to copy their DNA constantly. This makes them far more vulnerable to topotecan's DNA-trapping mechanism than healthy cells. The drug is especially effective in small-cell lung cancer and ovarian cancer because these tumors have very high replication rates and depend heavily on rapid DNA synthesis [8].
The trade-off is that topotecan also damages bone marrow cells, which divide rapidly to make new blood cells. This is why your white blood cell count (neutrophils) can drop dangerously low within 7–10 days of treatment. Your oncologist must monitor your blood counts closely and may delay or reduce your dose if neutrophils fall below safe thresholds [9].
Ask your oncologist: 'When will my first blood count drop, and what neutrophil level means we need to pause treatment?' Most patients see the lowest counts 7–10 days after each dose, so plan lab work accordingly.